Добірка наукової літератури з теми "634.049 3"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "634.049 3".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "634.049 3":
1
Deng, Lin, Bing Huang, Huai Yuan Zhao, Jia Yao Du, and Ling Gao. "Study on Modified PVA- H3BO3 Immobilization Microorganism Method for Hydrogen Production from Wastewater." Advanced Materials Research 634-638 (January 2013): 280–85. http://dx.doi.org/10.4028/www.scientific.net/amr.634-638.280.
Анотація:
A new immobilization microorganism (IM) method was built by adding sodium alginate, SiO2 and CaCO3 in gel and cross-linking with saturated H3BO3 aqueous solution with 2% CaCl2 for traditional PVA-H3BO3 method. The modified method was used for preparation IM for hydrogen production from waste water contained organics by sewage treatment plants’ sludge pretreated. The change rate of the IM balls diameter and unit hydrogen production were taken as the primary performance criterion of the IM. The modified IM method for hydrogen production from waste water contained organics was confirmed: 9% PVA and 0.9% sodium alginate for the embedding medium, saturated H3BO3 aqueous solution and 2% CaCl2 for cross-linking agent, and adding NaCO3 adjusting PH, 3%SiO2 and 0.5%CaCO3 for the support packing of IM balls, and the balls diameter of about 3mm. The modified IM balls had unit hydrogen production of 63.3% and total sugar removal rate of 143.4mL/h•L for washing model wastewater from ice cream factory, which contained 2000 mg/L total sugar and 5500mg/L COD, and higher mechanical strength. It were identified that the method could reduce outside surface’s shrink, and improve the homogeneous of inside endoporus structure of modified IM balls, and a similar inside microporosity and outside microporosity by SEM detection.
2
Bowmaker, Graham A., Effendy, John D. Kildea, Eban N. de Silva, and Allan H. White. "Lewis-Base Adducts of Group 11 Metal(I) Compounds. LXXI Synthesis, Spectroscopy and Structural Systematics of Some 1 : 2 Binuclear Adducts of Silver(I) Compounds with Triphenylarsine, [(Ph3As)2Ag(µ-X)2Ag(AsPh3)2], X = Cl, Br, I, SCN." Australian Journal of Chemistry 50, no. 6 (1997): 627. http://dx.doi.org/10.1071/c96037.
Анотація:
The syntheses and room-temperature single-crystal X-ray structural characterization of binuclear 1 : 2 adducts formed between silver(I) (pseudo-)halides, AgX, and triphenylarsine, AsPh3, for X = Cl, Br, I, SCN (1)–(4), are described. The chloride (1), obtained from 2-methylpyridine, is triclinic, P-1, a 10·410(2), b 12·716(2), c 14·196(6) Å, α 113·38(2), β 109·41(2), γ 75·08(1)°, Z = 1 (dimer); conventional R on F was 0·037 for No 3979 independent ‘observed’ (I > 3σ(I)) reflections. The bromide (2a), obtained from 2,6-dimethylpyridine, and iodide (3), obtained from a mixture of AgI/saturated KI in MeOH solutions, are isomorphous, monoclinic, P 21/c a≈ 24·2, b ≈ 13·9, c ≈ 20·2 Å, β ≈ 109·5°, Z = 4 dimers; R was 0·046 and 0·044 for No 5670 and 6039 respectively. The thiocyanate (4) has a similar cell, a 24·12(1), b 12·558(8), c 23·244(4) Å, β 110·11(3)°, Z = 4 dimers, R being 0·044 for No 7956; one of the thiocyanate ligands (which bridge in Ag-SCN-Ag mode) is disordered. A second polymorph of the bromide (2b) (from a mixture of AgBr/saturated KBr in H2O) is also monoclinic, P 21/c, a 14·121(8), b 25·577(3), c 21·968(2) Å, β 125·54(3)°, Z = 4 dimers (R was 0·047 for No 5715). Ag–As range between 2·568(1) and 2·633(1) Å throughout the series; in the isomorphous bromide and iodide, values increase slightly: 2·578(1)–2·611(1), cf. 2·601(2)-2·633(1) Å respectively. Ag–X are 2·568(2)-2·670(2) (Cl); 2·688(2)–2·715(2) (Br); 2·828(2)–2·856(1) Å (I); Ag-S, N for the ordered SCN group are 2·646(3), 2·255(6) Å. A redetermination of improved precision (R 0·035, No 6030) is reported for the triphenylphosphine/thiocyanate analogue. The far-infrared spectra of [(Ph3As)2Ag(µ-X)2Ag (AsPh3)2] show v(AgX) bands at 185, 145 (X = Cl), 145, 130, 106 (X = Br) and 121 cm-1 (X = I). The splittings and band widths reflect a decrease in the degree of distortion of the Ag(µ-X)2Ag units from a symmetrically bridged structure from X = Cl to I.
3
Long, Georgina V., F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo Antonio Ascierto, Luis Matamala, Pamela Salman, et al. "Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)." Journal of Clinical Oncology 40, no. 36_suppl (March 20, 2022): 360385. http://dx.doi.org/10.1200/jco.2022.40.36_suppl.360385.
Анотація:
360385 Background: RELATIVITY-047, a global, randomized, double-blind, phase II/III study, met its primary endpoint of progression-free survival (PFS). Relatlimab and nivolumab (RELA + NIVO) as a fixed-dose combination (FDC) demonstrated a significant PFS benefit (median PFS was 10.1 months [mo]; 95% CI, 6.4–15.7) with RELA + NIVO vs. 4.6 mo (95% CI, 3.4–5.6) with NIVO; hazard ratio (HR) 0.75 (95% CI, 0.6–0.9; p = .0055), with a manageable safety profile, compared to NIVO alone in patients with previously untreated metastatic or unresectable melanoma (Lipson EJ et al. J Clin Oncol 2021;39[15_suppl]:9503P). Here we report updated PFS and the first disclosure of secondary endpoints, overall survival (OS), and overall response rate (ORR). Methods: Patients were randomized 1:1 to receive RELA 160 mg + NIVO 480 mg FDC or NIVO 480 mg alone, given intravenously every 4 weeks, as previously described (Lipson EJ et al. J Clin Oncol 2021;39[15_suppl]:9503P). The primary endpoint of PFS per RECIST v1.1 was assessed by blinded independent central review (BICR). Secondary endpoints were OS and ORR by BICR, to be tested hierarchically. The OS boundary for statistical significance was p < .04302 (2-sided) based on 69% power for a target HR of 0.75. Results: Patients (714 patients) were randomly selected to receive RELA + NIVO (355 patients) or NIVO (359 patients). Median follow-up was 19.3 mo. Updated median PFS was 10.2 mo (95% CI, 6.5–14.8) with RELA + NIVO vs. 4.6 mo (95% CI, 3.5–6.4) with NIVO (HR 0.78; 95% CI, 0.6–0.9). Median OS was not reached (NR; 95% CI, 34.2–NR) with RELA + NIVO vs. 34.1 mo (95% CI. 25.2–NR) with NIVO (HR 0.80; 95% CI, 0.6–1.0; p = .0593). OS rates at 12 mo were 77.0% (95% CI, 72.2–81.1) vs. 71.6% (95% CI, 66.6–76.0) and at 24 mo were 63.7% (95% CI, 58.1–68.7) vs. 58.3% (95% CI, 52.7–63.4) with RELA + NIVO vs. NIVO, respectively. Subsequent systemic therapy rates and types were generally similar between treatment groups. Confirmed ORR per BICR was 43.1% (95% CI, 37.9–48.4) with RELA + NIVO vs. 32.6% (95% CI, 27.8–37.7) with NIVO. Complete responses were observed in 16.3% of patients on RELA + NIVO vs. 14.2% on NIVO. Grade 3/4 treatment-related adverse events (TRAEs) were observed in 75 (21.1%) patients on RELA + NIVO and 40 (11.1%) on NIVO. There were four treatment-related deaths in the RELA + NIVO group and two in the NIVO group. TRAEs (any grade) leading to treatment discontinuation were observed in 54 (15.2%) patients on RELA + NIVO and 26 (7.2%) on NIVO. Conclusions: RELA + NIVO continued to demonstrate a PFS benefit vs. NIVO alone in patients with previously untreated metastatic or unresectable melanoma, consistent with the primary analysis. RELA + NIVO demonstrated a 20% reduction in risk of death and numerically improved OS rates vs. NIVO, although statistical significance was not reached for this secondary endpoint. ORR was higher with RELA + NIVO vs. NIVO. The safety profile of RELA + NIVO remained manageable with no new or unexpected safety signals. Clinical trial information: NCT03470922.
4
Wang, Lin, Zhen Ping Wu, Yu Cheng Jiang, Bing Ren, Jian Huang, Lin Jun Wang, Yi Ben Xia, and Ju Gao. "Impact of the Oxygen Content on the Electronic Properties in Epitaxial Thin Films of Electron-Doped La0.9Hf0.1MnO3." Advanced Materials Research 634-638 (January 2013): 2485–88. http://dx.doi.org/10.4028/www.scientific.net/amr.634-638.2485.
Анотація:
Thin films of perovskite manganite La0.9Hf0.1MnO3 (LHMO) have been grown on (100) SrTiO3 single-crystal substrates with different growth pressures by pulsed laser deposition. The different transport behaviors of films have been fitted by various models. The results clearly demonstrate that oxygen pressure is an efficient way to change the transport behaviors of LHMO films. All the transport behaviors observed in LHMO films can be better fitted by Mott’s variable range hopping model than the other two models.
5
Schenker, Michael, Mikhail Klochikhin, Dmitry Kirtbaya, Laurent Mortier, Martin Gschnell, Caroline Robert, Nicolas Meyer, et al. "Abstract PO-009: Phase 3 KEYNOTE-630 study of adjuvant pembrolizumab in high-risk locally advanced cutaneous squamous cell carcinoma." Clinical Cancer Research 29, no. 18_Supplement (September 15, 2023): PO—009—PO—009. http://dx.doi.org/10.1158/1557-3265.aacrahns23-po-009.
Анотація:
Abstract Introduction: Among patients with high-risk locally advanced (LA) cutaneous squamous cell carcinoma (cSCC), approximately 20% experience local disease recurrence within 5 years after standard-of-care surgical resection and adjuvant radiotherapy. Better treatment options are needed for patients who experience recurrence after surgery. The PD-1 inhibitors pembrolizumab (pembro) and cemiplimab have shown durable antitumor activity in advanced metastatic cSCC. The randomized, double-blind, placebo-controlled, phase 3 KEYNOTE-630 (NCT03833167) trial will be conducted to evaluate adjuvant pembro in patients with resectable, high-risk, LA cSCC. Materials and Methods: Eligible patients will have histologically confirmed LA cSCC as the primary site of malignancy and have undergone complete macroscopic resection of all disease with ≥1 high-risk feature: histologically involved nodal disease with extracapsular extension, with ≥1 lymph node >2 cm in diameter or ≥2 lymph nodes involved; any gross cortical bone, skull base, and/or skull base foramen invasion; any index tumor with ≥2 of the following: tumor ≥4 cm with >6-mm depth or invasion beyond subcutaneous fat, multifocal perineural invasion for nerves <0.1 mm in diameter (≥3 foci) or any involved nerve ≥0.1 mm in diameter, poor differentiation and/or sarcomatoid and/or spindle cell histology, recurrent disease (recurrence within 3 years in the previously treated area), or satellite lesions and/or in-transit metastases, lymphatic or vascular involvement. Patients must have received adequate postoperative dose of hypofractionated or conventional radiotherapy, including a BED EQD2 >48 Gy, have ECOG PS of 0 or 1, and completed adjuvant radiotherapy ≥4 and ≤16 weeks from randomization. Patients are required to provide tumor tissue for PD-L1 testing and have an ECOG PS of 0 or 1. Approximately 570 patients will be randomly assigned 1:1 to pembro 400 mg IV every 6 weeks or placebo for approximately 1 year (≤9 cycles). Stratification factors are extracapsular extension, cortical bone invasion, and prior systemic therapy (all, yes vs no). Patients receiving placebo may be eligible to cross over to receive pembro (≤18 cycles) if first biopsy-proven recurrence occurs within 5 years. In the pembro arm, eligible patients may receive pembro retreatment for up to 18 cycles. The primary end point is recurrence-free survival per investigator assessment with biopsy confirmation and secondary end points include overall survival, health-related quality of life, and safety. Computed tomography/magnetic resonance imaging of disease-involved areas and associated lymph nodes will be performed at screening and every 12 weeks until the end of year 2, then every 6 months until the end of 5 years. Adverse events will be monitored throughout the study and for 30 days after treatment end and graded per NCI CTCAE v4.0. Results: Recruitment is underway at sites in Asia, Australia, Europe, and North and South America. Conclusions: Results of KEYNOTE-630 will elucidate the role of adjuvant pembro in patients with high-risk, LA cSCC. Citation Format: Michael Schenker, Mikhail Klochikhin, Dmitry Kirtbaya, Laurent Mortier, Martin Gschnell, Caroline Robert, Nicolas Meyer, Lukas Flatz, Stephane Dalle, Marie Beylot-Barry, Thomas Eigentler, Rachel Kloss Silverman, Burak Gumuscu, Jianda Yuan, Aase Bratland. Phase 3 KEYNOTE-630 study of adjuvant pembrolizumab in high-risk locally advanced cutaneous squamous cell carcinoma [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-009.
6
Lee, Seok, Yoo-Jin Kim, Chang-Ki Min, Byung-Sik Cho, Sung-Yong Kim, Ki-Seong Eom, Heeje Kim, et al. "Predictive Potential of Minimal Residual Disease Level after the First Imatinib Cycle on the Outcome of Allogeneic Stem Cell Transplantation in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia." Blood 110, no. 11 (November 16, 2007): 1098. http://dx.doi.org/10.1182/blood.v110.11.1098.1098.
Анотація:
Abstract Purpose: Previously, we demonstrated the positive impact of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation (SCT) in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) (Blood2005;105:3449). Here, we analyzed for risk factors that affect transplantation outcome, and focused particularly on the prognostic relevance of minimal residual disease (MRD) during treatment course. Patients and Methods: Fifty-two consecutive adults with Ph-positive ALL who completed SCT following imatinib therapy were enrolled in this prospective study. MRD assessment was performed using real-time quantitative polymerase chain reaction. Results: Forty-three (87.8%) of the 49 evaluable patients showed a decrease in MRD after imatinib therapy. Molecular remission rates were 18.4% and 44.4% after the first and second imatinib cycles, respectively. Forty-eight (92.3%) of the 52 patients received SCT during first complete remission. With a median follow-up of 42 months after SCT, the actuarial 3-year relapse and disease-free survival (DFS) rates were 22.9% ± 6.6% and 67.3% ± 7.2%, respectively. An MRD level of ≥ 10−3 after the first imatinib cycle was found to be the most powerful predictor of relapse (47.5% ± 14.3% versus 11.4% ± 6.4%, P = .009) and DFS (45.0% ± 13.2% versus 80.9% ± 8.0%, P = .016). The presence of chronic graft-versus-host disease was also found to be associated with a lower relapse (5.3% ± 5.1% versus 37.6% ± 10.8%, P = .029) and better DFS (82.0% ± 9.5% versus 62.4% ± 10.8%, P = .039). Conclusion: In the setting of allogeneic SCT following imatinib therapy, prospective MRD monitoring may allow us to identify subgroups of Ph-positive ALL patients at high risk of relapse at an earlier treatment stage.
7
Yang, Jian Jun, Wen Hui Ma, Jie Yu, Xiu Hua Chen, Jie Xing та Rui Li. "Preparation of La0.9SR0.1Ga0.8Mg0.2O3-δ Electrolyte Films Deposited by RF Magnetic Sputtering". Advanced Materials Research 634-638 (січень 2013): 2550–54. http://dx.doi.org/10.4028/www.scientific.net/amr.634-638.2550.
Анотація:
La0.9Sr0.1Ga0.8Mg0.2O3-d (LSGM) electrolyte materials were synthesized using solid state reactions. The LSGM material film was deposited by radiofrequency magnetic sputtering on La0.7Sr0.3Cr0.5Mn0.5O3-d (LSCM) substrates. The analysis results show the films did not form but formed some “mountains” when deposited for 4 h. While the depositing time extended to 12 h, a dense and uniform film with perovskite phase was obtained, and the element amounts of the film were closed to those of the LSGM materials.
8
Semenova, Lioubov I., and Allan H. White. "Structural Systematics of Rare Earth Complexes. XVII Hydrated 1 : 1 Adducts of 2,2′:6′,2″-Terpyridine with the Lanthanoid(III) Bromides and Some Binuclear Hydroxy-Bridged Dimers." Australian Journal of Chemistry 52, no. 6 (1999): 539. http://dx.doi.org/10.1071/ch98048.
Анотація:
Room-temperature single-crystal X-ray structural characterizations are recorded for hydrated lan- thanoid(III) bromide/2,2′:6′,2″-terpyridine (tpy) (1 : 1) complexes, showing all to be ionic and of the form [(tpy)Ln(OH2)x]Br3.yH2O, where x and y are 6 and 1 for the isomorphous series Ln = La(-)Er (and intermediate members, by presumption), and 5 and various values for Ln = Tm, Yb, Lu. Crystals of [(tpy)Ln(OH2)6]Br3.H2O are monoclinic, P 21/c, a ≈ 8·5, b ≈ 18, c ≈ 16·3 Å, β ≈ 108°, Z = 4; for Ln = La, Er, conventional R values on |F| were 0·048, 0·080 for No 4027, 1347 ‘observed’ (I > 3σ(I)) diffractometer reflections respectively. The complex [(tpy)Tm(OH2)5]Br3.H2O is monoclinic, P 21/c, a 8·506(4), b 17·376(1), c 15·951(6) Å, β 106·87(3)°, Z = 4, (quasi-)isomorphous with the Ln = La-Er array, R 0·065 for No 2067. [(tpy)Yb(OH2)5]Br3.4H2O is triclinic, P 1, a 11·902(2), b 11·639(3), c 9·831(2) Å, α 98·92(2), β 106·84(2), γ 92·42(2)°, Z = 2, R 0·062 for No 3422, while [(tpy)Lu(OH2)5]Br3.H2O is monoclinic, P 21/n, a 13·635(8), b 9·022(5), c 19·03(1) Å, β 99·02(5)°, Z = 4, R 0·043 for No 3139. Despite a common N3LnO5 coordination sphere in the last three compounds, subtle differences are found in stereochemistry; in the N3LnO6 array, one of the outer water molecules becomes progressively detached as the lanthanoid radius contracts. Some tendency is found toward the end of the lanthanoid series toward the formation of di(hydroxy-bridged) neutral dimers, Ln(OH)Br2/tpy/H2O(1 : 1 : 8)(×2), [(tpy)(H2O)3Ln(µ-OH)2Ln(OH2)3(tpy)]Br4.10H2O, monoclinic, C 2/c, a ≈ 19·5, b ≈ 14·5, c ≈ 17·1 Å, β ≈ 92°, Z = 4 dimers, thus far defined by full determinations for the extrema Lu = Er, Lu (and Y), R 0·055, 0·043, (0·047) for No 3141, 4591, (2991) respectively; the dimer is disposed about a crystallographic 2 -axis. An Ln = Dy example, seemingly isomorphous, has also been characterized by cell determination.
9
Lipson, Evan J., Hussein Abdul-Hassan Tawbi, Dirk Schadendorf, Paolo Antonio Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, et al. "Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047)." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 9503. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.9503.
Анотація:
9503 Background: Immune checkpoint inhibitor therapy has revolutionized the treatment of patients with advanced melanoma. However, novel combinations are needed to optimize the benefit-risk profile. Lymphocyte-activation gene 3 (LAG-3) regulates an immune checkpoint pathway, which inhibits T-cell activity, and is upregulated in many tumor types including melanoma. Relatlimab (RELA), a human IgG4 LAG-3-blocking antibody, restores effector function of exhausted T cells. RELA in combination with nivolumab (NIVO; anti-programmed death [PD]-1) modulates potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. RELATIVITY-047 is a global, randomized, double-blind, phase II/III study evaluating a novel immune checkpoint inhibitor combination of RELA+NIVO as a fixed-dose combination (FDC) treatment in first-line advanced melanoma. Methods: Patients with previously untreated advanced melanoma were randomized 1:1 to receive RELA 160 mg + NIVO 480 mg FDC intravenously (IV) every 4 weeks (Q4W) or NIVO monotherapy 480 mg IV Q4W, stratified by LAG-3 expression, programmed death ligand 1 expression, BRAF mutation status, and AJCC (v8) M stage. The primary endpoint was progression-free survival (PFS) per RECIST v1.1 as assessed by blinded independent central review. Secondary endpoints were overall survival and objective response rate. PFS in prespecified subgroups and safety were additional objectives. Results: 714 patients were randomized to RELA+NIVO FDC (n = 355) or NIVO (n = 359). Patient characteristics were well balanced between treatment groups. Median follow-up was 13.2 months. Median PFS in the RELA+NIVO FDC group (10.1 months [95% CI, 6.4–15.7]) was significantly longer than in the NIVO group (4.6 months [95% CI, 3.4–5.6]; hazard ratio, 0.75 [95% CI, 0.6–0.9]; P = 0.0055). PFS rates at 12 months were 47.7% (95% CI, 41.8–53.2) and 36.0% (95% CI, 30.5–41.6) for RELA+NIVO FDC and NIVO, respectively. PFS favored RELA+NIVO FDC across key prespecified subgroups. The incidence of grade 3/4 treatment-related adverse events (TRAEs) was higher in the RELA+NIVO FDC group (18.9%) versus NIVO (9.7%). There were 3 treatment-related deaths with RELA+NIVO FDC and 2 with NIVO. TRAEs (any grade) led to treatment discontinuation in 14.6% and 6.7% of patients in the RELA+NIVO FDC and NIVO groups, respectively. Conclusions: First-line treatment with RELA+NIVO FDC demonstrated a statistically significant PFS benefit compared to NIVO monotherapy in patients with advanced melanoma. RELA+NIVO FDC was well tolerated with a manageable safety profile and without unexpected safety signals. This is the first phase III study of a novel FDC to demonstrate a clinically meaningful benefit by dual inhibition of the LAG-3 and PD-1 pathways. Clinical trial information: NCT03470922.
10
Cao, Qin Bo, Shu Ming Weng, Chen Xiu Li, Shao Jun Bai, and Dan Liu. "Investigation on Beneficiation Strategy for Collophane." Advanced Materials Research 634-638 (January 2013): 3404–7. http://dx.doi.org/10.4028/www.scientific.net/amr.634-638.3404.
Анотація:
Phosphate being one of the three major nutrients required for agricultural plant growth usually presents as collophane in China. Since fine phosphate and other gauge minerals associate with each other and form intergrowth, the beneficiation of collophane is extremely difficult. In this paper, the flotation strategy for a low grade collophane ore from Guizhou province in China was studied in detail. Direct, reverse and direct-reverse combined flotation sheets were employed to collophane flotation. The results reveal that direct-reverse flotation is a suitable flotation flow sheet for this collophane ore. With direct-reverse flotation sheet, the grade of P2O5 in concentrate is 33%, which is improved by 3% comparing direct flotation and P2O5 recovery could achieve 80%. In addition, content of MgO decreased to 0.9%, which satisfied the requirement of wet-process phosphoric acid.
Книги з теми "634.049 3":
1
Повалій, Л. В. Виховання підлітків у неповній сім"ї. Київ: Педагогічна думка, 2008.
2
Oliveira, Mário Cézar Amorim de, Nilson de Souza Cardoso, and Jaqueline Rabelo de Lima. Itinerários de resistência: pluralidade e laicidade no Ensino de Ciências e Biologia. Editora Realize, 2021. http://dx.doi.org/10.46943/viii.enebio.2021.01.000.
Анотація:
Você tem em mãos o e-book com os Anais do ENEBIOnLine, a edição totalmente à distância (ou remota, ou virtual, ou on-line, como queira! rs) do VIII Encontro Nacional de Ensino de Biologia (VIII ENEBIO), do VIII Encontro de Ensino de Biologia da Regional Nordeste (VIII EREBIO-NE) e do II Simpósio Cearense de Ensino de Biologia (II SCEB). Uma edição histórica, em vários sentidos: 1. A primeira edição completamente não presencial dos nossos encontros de Ensino de Biologia; 2. A primeira edição organizada e realizada durante uma pandemia de grandes proporções que causa (ainda, infelizmente) uma crise sanitária sem precedentes na história mundial; e 3. Uma edição que tem “história pra contar”, exatamente em virtude desses contextos. Em 2018, no VII Encontro Nacional de Ensino de Biologia (VII ENEBIO) e I Encontro Regional de Ensino de Biologia (I EREBIO-NORTE), estávamos muito animados em trazer de volta para o Nordeste esse evento que bianualmente congrega nossa comunidade sbenbiana e tem o papel fundamental de dar continuidade e ampliar as ações da SBEnBio, promovendo interações de profissionais que atuam em diversos níveis e ambientes educativos no ensino de Ciências e de Biologia. Além disso, pensávamos em consolidar o EREBIO-NE como um importante espaço acadêmico-científico de troca e aprendizados entre professores e pesquisadores da região. Esses encontros congregam pesquisadores dos campos do Ensino de Ciências e Biologia, professores do ensino superior e da educação básica, além de estudantes das Licenciaturas em Ciências Biológicas e afins, alcançando quatro importantes segmentos de investimento na educação científica de qualidade. Empolgados com a expressiva participação numérica alcançada nos encontros nacionais anteriores e com a possibilidade de mitigar a carência de eventos dessa natureza e magnitude na região nordeste, em 2019 submetemos três propostas de tema gerador a uma enquete pública nas redes sociais. O tema gerador escolhido para o VIII ENEBIO, VIII EREBIO-NE e II SCEB, foi Itinerários de Resistência: Pluralidade e Laicidade no Ensino de Ciências e Biologia. Um tema que nos possibilitaria propor debates sobre questões pertinentes ao contexto social, político e educacional que o país atravessava e que acreditávamos que impactariam a formação inicial e continuada tanto quanto o trabalho de professores de Ciências e Biologia, tais como: as novas Diretrizes Curriculares Nacionais para a Formação Inicial de Professores, as recém aprovadas Base Nacional Comum Curricular para o Ensino Fundamental e para o Ensino Médio, além de questões sócio ambientais e culturais, educação para as relações étnico-raciais, educação no campo, educação indígena, relação entre conhecimento científico e conhecimentos de outras naturezas (religiosos, senso comum etc.), dentre tantas outras importantes questões. Nem imaginávamos que um vírus, que ironia, nos imporia mudanças... ainda no final de 2019 vimos nos noticiários o surto do SARS-CoV-2 na China... graças à nossa formação específica (em Ciências Biológicas) e à lembrança de situações anteriores, como a do surto da Síndrome Aguda Respiratória Grave (SARS) em 2002-2003, sabíamos que poderíamos estar diante não apenas de uma mera “gripezinha”, mas mantivemos os planos do evento que estava agendado para acontecer no período de 29 de Abril a 02 de Maio de 2020. Tínhamos um enorme interesse em promover o debate acerca das experiências dos professores e pesquisadores que atuam em diferentes espaços e níveis de escolaridade e refletir sobre como as características da pluralidade e laicidade necessárias a uma educação básica democrática e inclusiva, especialmente a educação científica, estavam, e ainda estão hoje, vulneráveis no contexto dos atuais projetos e políticas educacionais. Nesse contexto, debater conflitos, propor ações e compartilhar experiências eram os desafios que nos moviam a pensar itinerários de resistência que caminhassem na direção do fortalecimento da profissão docente e do ensino de Ciências e de Biologia. Com o aumento do número de casos de infecções na China e com sua disseminação pela Europa, nos acendeu o alerta para um eventual adiamento. Em março, o primeiro caso no Brasil é noticiado, mais tensão e mais apreensão. Tivemos uma primeira onda, da qual, para alguns especialistas, nunca saímos, decidimos, portanto, após as primeiras medidas de isolamento social, adiar a realização do Encontro para acontecer, ainda presencialmente, de 02 a 04 de setembro de 2020. Em 31 de maio, já somávamos mais de 29 mil vidas ceifadas no país pela COVID-19, em meio a negacionismos de todas as ordens que indicavam que o quadro provavelmente pioraria. Em junho de 2020, a Coordenação Organizadora Local, em concordância com a Diretoria Executiva Nacional (DEN) da SBEnBio e seu Conselho Deliberativo Nacional (CDN), comunicava o adiamento do evento por tempo indeterminado. Nesse momento, tínhamos indicativos de que poderíamos contar em breve com uma vacina, mas não havia prazo para que isso acontecesse. O Ceará e outros estados nordestinos estavam em lockdown, o país estava atônito frente à disseminação do vírus e ao negacionismo dos que deveriam estar lutando para combatê-lo. Final do ano de 2020, apesar de uma pequena queda do número de mortes no país e do anúncio de vacinas por laboratórios e institutos como o Butantan e a Fiocruz, as exitosas experiências de nossa parceira, Realize Eventos Científicos, na organização de eventos nacionais on-line, nos estimulou a retomar a organização do evento e considerar a possibilidade de sua realização nesse modelo. Seria uma aventura! Mas será que a vacinação não possibilitaria nos encontrarmos presencialmente, já em 2021? As estimativas não eram nada animadoras. Tudo indicava que o foco do governo federal seria o “tratamento precoce”, sabidamente ineficiente. Enfim, nos apegamos a experiência de nossa parceira e, em novembro de 2020, anunciamos o novo formato do evento, nascia o ENEBIOnLine! E foi contando com expressiva compreensão e apoio da comunidade sbenbiana que, mesmo que registrado descontentamentos, prevaleceu a decisão consciente ante a crise sanitária que ainda enfrentávamos no final de 2020 e início de 2021; e de 25 a 29 de janeiro aconteceu o VIII ENEBIO, VIII EREBIO-NE e o II SCEB, no formato totalmente on-line. Mantivemos praticamente a mesma programação, apesar do contexto da pandemia de COVID-19 e de suas implicações para a nossa área, como o impacto do ensino remoto na educação científica e formação docente, terem permeado inevitavelmente os debates nas palestras, mesas redondas e sessões de apresentação de trabalho. Podemos dizer que foi um “sucesso de público e de crítica”, com 909 credenciados participando das seis mesas redondas, palestras de abertura e encerramento, reunião ampliada da SBEnBio, painel temático reunindo as ex-presidentas e os ex-presidentes da associação... e tudo no conforto e na segurança de nossos lares. Uma decisão que já durante o evento se mostrava acertada, tendo em vista o recrudescimento da crise sanitária, com aumento alarmante do número de mortos (hoje, já somamos mais de 265.500 vidas perdidas para a COVID-19, segundo o último balanço do consórcio de veículos de imprensa), colapso da rede de atendimento hospitalar e que, possivelmente, será agravada em função da morosidade da vacinação no país associada ao “jeitinho brasileiro” de desobedecer as normas básicas de (auto)proteção contra a infecção. Apesar dos tempos terríveis que aparentemente ainda haveremos de enfrentar, esperamos que o reconhecimento pelo STF da perseguição jurídica sofrida pelo nosso ex-presidente da República... ops (desculpem-nos o ato falho! rs)... esperamos que a publicação desse e-book com os Anais do ENEBIOnLine, contendo a íntegra dos 632 trabalhos apresentados durante o evento, chegue como um sopro de esperança de que dias melhores virão! De que depois da peste e da tempestade, virá a bonança... de que, no segundo semestre de 2022, todes vocês poderão estar conosco em Fortaleza, Ceará, para o IX ENEBIO, IX EREBIO-NE e III SCEB... para sentir o calor da ‘Terra da Luz’ e do abraço que não pôde ser dado, para debater sobre o Ensino de Biologia, cada dia mais necessário no enfrentamento do negacionismo científico e das fake news que adoecem de morte o Brasil.
Частини книг з теми "634.049 3":
1
"3 Da‘wa after the Prophet, circa 632–1100 CE." In Da'wa, 65–90. Edinburgh University Press, 2021. http://dx.doi.org/10.1515/9781474451543-009.
2
Gostin, Lawrence O., Ronald Bayer,, and Amy L. Fairchild. "Ethical and Legal Challenges Posed by Severe Acute Respiratory Syndrome Implications for the Control of Severe Infectious Disease Threats." In Public Health Ethics, 261–77. Oxford University PressNew York, NY, 2006. http://dx.doi.org/10.1093/oso/9780195180848.003.0021.
Анотація:
Abstract Not long after the first reports of what ultimately would be called severe acute respiratory syndrome (SARS) began to appear in February 20031, 2 and as nations and the international community began to confront the spread of the new disease, it became clear that a host of ethical and legal issues had begun to surface. Indeed, not since the first years of the HIV/AIDS pandemic in the mid-l980s and the alarm over multidrug-resistant tuberculosis in the early 1990sdid it seem that so many issues touching on the core ethical questions posed by public health had to be addressed simultaneously. In several respects, SARS took society back to a pretherapeutic era with no definitive diagnostic test, a nonspecific case definition, and no effective vaccine or treatment. From I November 2002, to 1 July 2003, 8,445 cases were reported to the World Health Organization (WHO); among these, 5,327 (63%) were from China, 1,755 (20%) from Hong Kong, 678 (8%) from Taiwan, 252 (3%) from Canada, and 206 (2%) from Singapore. There were 812 deaths. Comparatively, the United States, with 73 cases (0.9%) and no deaths, was spared.
3
"TABLE8TocolDerivativeContentinCerealGrainsTocolderivatives ( m g / 100g ) aGrainsa -T a -T -3 1 3 -T I 3 -T -3 y -T y -T -3 6 -T 6 -T -3 TotalRef . Barley0 . 2 -0 . 4 1 . 1 -1 . 3 0 . 0 4 -0 . 4 0 . 3 -0 . 7 0 . 0 3 -0 . 5 0 . 2 0 . 0 1 -0 . 040 . 1 6 < 5 . 030 . 4 1 . 3 0 . 3 0 . 7 0 . 050 . 2 0 . 1 -8 9 0 . 5 1 . 3 0 . 020 . 7 0 . 070 . 8 0 . 020 . 0750 . 3 1 . 6 < 0 . 1 0 . 6 0 . 1 0 . 6 < 0 . 1 -9 0Genotype0 . 7 2 -1 . 162 . 3 8 -4 . 300 . 0 5 -0 . 130 . 3 1 -1 . 210 . 0 4 -0 . 120 . 2 4 -0 . 960 . 0 4 -0 . 140 . 0 2 -0 . 204 . 2 2 -8 . 0091Location0 . 8 8 -1 . 113 . 0 5 -3 . 630 . 002 -0 . 190 . 6 7 -0 . 750 . 070 . 5 0 -0 . 560 . 0 4 -0 . 130 . 0 7 -0 . 115 . 6 7 -6 . 0891Malt1 . 003 . 070 . 140 . 460 . 040 . 390 . 040 . 065 . 292Spentgrain2 . 029 . 210 . 311 . 600 . 091 . 760 . 120 . 1815 . 392Corn0 . 6 -2 . 1 0 . 2 -0 . 5 -0 . 5 -1 . 1 3 -0 . 6 0 . 2 0 . 4 3 . 8 0 . 5tr890 . 1 -2 . 3 0 . 3 -0 . 7 1 . 1 -7 . 1 0 . 1 -1 . 9 2 . 6 -1 0 . 29Millet0 . 05tr1 . 3 0 . 489 -0 . 1 < 0 . 1 0 . 1 1 . 7 < 0 . 1 0 . 690Bulrushmillet0 . 1 3 -5 . 540 . 530 . 080 . 25Foxtailmillet0 . 190 . 040 . 042 . 780 . 065Fingermillet0 . 320 . 050 . 031 . 7 6 -5 Pearlmillet0 . 041 . 5 -0 . 355 -O ats0 . 3 -1 . 7 0 . 7 -1 . 1 0 . 1 -0 . 2 0 . 1 -0 . 3 0 . 3 -3 0 . 7 0 . 7 0 . 2 0 . 1 0 . 3 -8 9 1 . 3 -4 . 0 0 . 2 -6 . 3 0 . 3 -0 . 5 0 . 3 -1 . 1 0 . 7 -6 . 1 0 . 910 . 140 . 321 . 3 -3 . 011Genotype0 . 5 5 -0 . 960 . 9 1 -1 . 860 . 0 7 -0 . 130 . 0 5 -0 . 150 . 0 5 -0 . 130 . 0 0 -0 . 061 . 9 -3 . 091Location0 . 7 2 -0 . 961 . 1 7 -1 . 830 . 0 7 -0 . 110 . 0 5 -0 . 140 . 0 8 -0 . 110 . 0 1 -0 . 032 . 1 -3 . 191RiceBrownrice0 . 6 0 . 4 0 . 1 < 0 . 010 . 1 0 . 7 < 0 . 190Polishedrice < 0 . 1 0 . 1 < 0 . 1 < 0 . 1 < 0 . 1 0 . 3 < 0 . 190Milledrice0 . 0 5 -0 . 3 0 . 2 -0 . 5 0 . 1 -0 . 3 -< 0 . 0440 . 3tr0 . 3 0 . 5 0 . 04890 . 060 . 080 . 260 . 020 . 025 -R ye0 . 5 -1 . 8 0 . 7 -1 . 5 0 . 3 -0 . 7 0 . 8 -0 . 9 0 . 6 -3 0 . 8 1 . 3 0 . 4 0 . 9 0 . 689Flour0 . 6 0 . 4 0 . 3 0 . 6 -9 0Meal1 . 0 1 . 4 0 . 3 1 . 190Sorghum0 . 081 . 155Triticale0 . 911 . 030 . 301 . 515Winter0 . 7 -0 . 9593Spring1 . 3 5 -1 . 4593 -W heat1 . 0 0 . 2 0 . 4 1 . 9 -5 0 . 9 -1 . 8 0 . 3 -0 . 7 2 . 5 -3 . 6 4 . 9 -5 . 831 . 0 0 . 4 0 . 9 2 . 5 0 . 0889aTocopherolsincludea -T , 0 -T , y -T , and5 -T , andtocotrienolsincludea -T -3 , 0 -T -3 , y -T -3 , andS -T -3 . ( -) denotedatanotreported ." In Handbook of Cereal Science and Technology, Revised and Expanded, 449–94. CRC Press, 2000. http://dx.doi.org/10.1201/9781420027228-47.
Тези доповідей конференцій з теми "634.049 3":
1
Mohammed, Zakriya, Bruna Paredes, and Mahmoud Rasras. "Ultra-Compact and Ultra-Broadband Mode (De)Multiplexer Utilizing an Asymmetrical Coupler with SWG and Cascaded Tapered Waveguide." In Optical Fiber Communication Conference. Washington, D.C.: Optica Publishing Group, 2024. http://dx.doi.org/10.1364/ofc.2024.m3b.3.
Анотація:
A 25 μm two-mode (de)multiplexer on a silicon-on-insulator platform is demonstrated. Operating in 200 nm bandwidth, it achieves low insertion-loss (< 0.9 dB), minimal crosstalk (< 18.8 dB), and clear eye diagrams at 64 Gbit/s.
2
Ma, Jian, Yoshinao Taketomi, Yeshaiahu Fainman, Joseph E. Ford, Sing H. Lee, and Ken’ichi Chino. "Enhanced photorefractive effects with a de field and moving grating in GaP at 633 nm." In Optical Computing. Washington, D.C.: Optica Publishing Group, 1991. http://dx.doi.org/10.1364/optcomp.1991.me2.
Анотація:
Photorefractive (PR) devices have found applications in optical computing, image processing and pattern recognition[1–3], because PR materials provide unique features such as real time operation, optical gain, storage, nonlinear operations, phase conjugation and correlation. New PR materials are being investigated in order to meet the device and system requirements of sensitivity, speed, and operation wavelength (e.g., response to the near infrared spectral range for systems operated with semiconductor lasers). Compound semiconductors may satisfy these requirements. For example, optical signal amplification by two-beam coupling and amplified phase-conjugate beam reflection by four-wave mixing have been reported in GaAs[4] and InP[5] at the wavelength of 1.06 μm. Recently, GaP[6–7] was shown to possess a relatively weak PR effect in the spectral range of 0.6 to 0.9 μm. In this manuscript we report enhancement of the PR effect in GaP using an externally applied electric field and moving grating. In particular, two- and four-wave mixing experiments were used to demonstrate a gain coefficient of Γ = 1.9 cm–1 and a phase conjugate reflectivity, R= 4.5%. In addition, several figures of merit of GaP, i.e., steady-state index change, absorption coefficient, response time and PR sensitivity were characterized.
3
Carvalho, Gabriel Domingos, MAIZA MARCELINO DE SOUZA, and KAYNAN DE MOURA FÓSSE. "AVALIAÇÃO DOS ASPECTOS PATOLÓGICOS DE TARTARUGAS MARINHAS NA ÁREA DAS BACIAS DE CAMPOS E ESPÍRITO SANTO - BRASIL." In II Congresso Brasileiro de Biodiversidade Virtual. Revista Multidisciplinar de Educação e meio ambiente, 2022. http://dx.doi.org/10.51189/ii-conbiv/6341.
Анотація:
Introdução: As tartarugas são consideradas sentinelas da saúde ambiental e sofrem com vários fatores antrópicos, seja por avanço costeiro, poluição, atividades pesqueiras, portuárias, e de extração de petróleo e gás, dentre outros. Objetivo: Este trabalho teve como objetivo realizar um levantamento de dados sobre as tartarugas marinhas encalhadas, encontradas e recolhidas pelo Programa de Monitoramento de Praias das Bacias de Campos e Espírito Santo (PMP-BC/ES). Material e Métodos: A coleta de dados foi realizada no Sistema de Informação de Monitoramento da Biota Aquática (SIMBA), mantidos pela Petrobrás, por meio do acesso ao perfil público do sistema. Foram extraídos os dados referentes aos esforços de monitoramento e ocorrências de fauna alvo (quelônios) e resultados de exames anatomopatológicos. Foram analisados dados referentes à 3125 tartarugas recolhidas no intervalo de 04/10/2017 a 20/03/2021. Resultados: A espécie predominante nos registros foi Chelonia mydas (75,7%), seguida por Caretta caretta (16,1%), Lepidochelys olivacea (7,3%), Eretmochelys imbricata (0,8%) e Dermochelys coriacea (0,1%). O registro das suspeitas clínicas, que relacionam as causas das mortes das tartarugas, aponta para um maior número de mortes por afogamento (41,5%), seguido de mortes por processos infecciosos (33,8%), causas indeterminadas (21,7%), e trauma (3%). O número de tartarugas que encalhou em consequência de ações antrópicas foi, predominantemente, devido às interações com artefatos de pesca (45,3%), seguido de resíduos sólidos (39,1%), além de outras interações, como com embarcações pesqueiras (10,5%), indícios de agressão ou caça (4,8%) e presença de resíduos de óleo (0,2%). Foram registrados 377 animais com a presença de parasitismo, em quatro espécies de tartarugas, com predomínio dos registros em C. mydas. Somente sete animais foram registrados com fibropapilomatose, sendo todos C. mydas. Conclusão: O êxito na conservação de espécies marinhas migratórias, como as tartarugas, necessita de medidas mitigadoras efetivas, que reduzam os impactos antrópicos sobre essas espécies. Sendo assim, são necessários a identificação, o mapeamento, a avaliação e o monitoramento das ameaças e das características dessas populações vulneráveis, de modo a subsidiar ações de elaboração de estratégias de conservação e preservação de tartarugas e de outras espécies marinhas.
4
"PS-039 - CONSUMO DE ALCOHOL Y TABACO E INCIDENCIA DE FACTORES DE RIESGO CARDIOVASCULAR EN NUEVOS PACIENTES DIAGNOSTICADOS DE ESQUIZOFRENIA A TRAVÉS DE LA COHORTE DE EPICHRON." In 24 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE PATOLOGÍA DUAL. SEPD, 2022. http://dx.doi.org/10.17579/abstractbooksepd2022.ps039.
Анотація:
1. Objetivos El objetivo principal de este estudio es caracterizar los pacientes diagnosticados de esquizofrenia y consumo de alcohol y tabaco, y como objetivo específico valorar el riesgo que tienen estos pacientes de desarrollar factores de riesgo cardiovascular(FRCV) como la hipertensión arterial, diabetes mellitus tipo 2, dislipemia y obesidad. 2. Material y métodos Estudio descriptivo donde se seleccionaron los pacientes procedentes de la cohorte EpiChron (1.3 millones de habitantes de Aragón) que presentaban en las bases de datos un nuevo diagnóstico de esquizofrenia y otros trastornos psicóticos entre el 1 de enero de 2011 y 31 de diciembre de 2017 y que tenían consumo activo de alcohol y/o tabaco. Se analiza la presencia de una nueva prescripción de antidiabético oral, antidislipémico, o antihipertensivo, o bien el diagnóstico de obesidad, desde la fecha índice hasta la finalización del seguimiento. Se empleó la técnica de chi-cuadrado para comparar las variables categóricas. 3. Resultados y conclusiones Se diagnosticaron 796 pacientes con esquizofrenia. De los cuales 164(20.6%) consumían tabaco y entre éstos: 17 toman antihipertensivos, 3 antidiabéticos, 20 antidislipémicos y 14 tienen diagnóstico de obesidad. Se encuentra significación estadística (p<0.05) para el grupo de antidiabéticos y tabaco. 43(5.4%) pacientes consumían alcohol. De los pacientes que consumen alcohol: 3 tienen prescritos antihipertensivos, ninguno antidiabéticos, 7 antidislipémicos y 2 tienen diagnóstico de obesidad, sin encontrar ninguna significación estadística. Destaca el porcentaje bajo registrado en tabaco: 164 personas fumadoras frente 632 sin tabaco registrado. Se ha visto en otros estudios que el tabaco es uno de los principales FRCV que recogen los estudios, suponiendo un incremento desde 15-25% en el riesgo de efectos cardiovasculares de pacientes con esquizofrenia y con uno de los valores predictivos más alto para mortalidad. Puede que estemos frente a un menor registro de estos factores en esta población.
5
Балашова, А. В., Л. В. Мачехина, Е. Н. Дудинская, И. Н. Стражеско та О. Н. Ткачева. "СОСТОЯНИЕ УГЛЕВОДНОГО ОБМЕНА У ДОЛГОЖИТЕЛЕЙ". У Сборник тезисов III Конференции по лечению и диагностике сахарного диабета «Фундаментальная и клиническая диабетология в 21 веке: от теории к практике». ФГБУ «НМИЦ эндокринологии» Минздрава России, 2023. http://dx.doi.org/10.14341/diaconfiii25-26.05.23-10.
Анотація:
ЦЕЛЬ: оценить состояние углеводного обмена у долгожителей Москвы и близлежащих регионов.
МАТЕРИАЛЫ И МЕТОДЫ: в это когортное исследование включались лица в возрасте 90 лет и старше, давшие письменное согласие на участие. В домашних условиях проводилась комплексная гериатрическая оценка, включавшая сбор анамнеза, применение стандартных гериатрических шкал и опросников, выполнение антропометрических измерений. Всем участникам оценивались следующие лабораторные показатели: глюкоза, инсулин, индекс инсулинорезистентности HOMA-IR, гликированный гемоглобин (HbA1c). Интерпретация состояния углеводного обмена проводилась согласно актуальным на 2022 г. клиническим рекомендациям. Статистический анализ данных проводился с помощью языка программирования R версии 4.1.3. Количественные переменные представлены в виде Me (Q1-Q3). Для сравнения непараметрических значений применялся критерий Краскела-Уоллиса, номинальных переменных – χ2 Пирсона или точный критерий Фишера. Исследование было одобрено локальным этическим комитетом.
РЕЗУЛЬТАТЫ: за период с 2019 по 2022 г. в исследование было включено 3 811 человек (75,4% женщины) в возрасте 92 (91–94) года. Средний индекс массы тела составил 25,4 (23-28,2) кг/м2, доля участников с ожирением составила 15,2%, при этом у 72,9% пациентов были значения окружности талии соответствовали абдоминальному ожирению. Средние значения глюкозы составили 5 (4,5 – 5,7) ммоль/л, HbA1c 5,6 (5,4 – 5,9)%, HOMA-IR – 1,5 (0,9 – 2,6).
В группу СД были отнесены 20,5% (780); предиабета – 16,1% (613). Все случаи СД были интерпретированы как 2 тип. В группе с СД большая часть пациентов 71,7% имела диагноз на основании данных анамнеза; у 28,3% пациентов были впервые выявлены значения параметров углеводного обмена в диабетическом диапазоне. С клинической точки зрения, значения показателей углеводного обмена в группе пациентов с СД были близки к значениям в группе предиабета: глюкоза - 6,3 (5,1 - 7,9) и 5,9 (5 - 6,4) ммоль/л, HbA1c 6,2 (5,6 - 7) и 6,1 (6 - 6,2)%, HOMA-IR 2,3 (1,3 - 6,1) и 2,2 (1,4 - 4,5), соответственно. При этом лишь 4,8% (38) участников с СД получали сахароснижающую терапию (ССТ): 3,8% (30) монтерапию инсулином, 0,6% (5) – терапию пероральными сахароснижающими препаратами, 0,4% (3) – комбинированную терапию. Несмотря на то, что в группе с впервые выявленным СД значения показателей углеводного обмена были статистически значимо выше, чем в группе с ранее выявленным СД (глюкоза 7,4 и 5,9 ммоль/л; HbA1c 6,8 и 6,1%, соответственно), они всё равно были ниже предполагаемых целевых значений для этой возрастной категории. Дополнительно пациенты были разделены на возрастные подгруппы: 90-94 лет (3091), 95-99 лет (674), >100 лет (46); достоверных различий в значениях показателей глюкозы и HbA1c, частоте СД и предиабета между группами получено не было.
ВЫВОДЫ: доля пациентов с СД в исследованной когорте долгожителей была практически сопоставима с данными о распространённости СД в группе пожилых людей, при этом показатели углеводного обмена указывали на компенсацию углеводного обмена даже при низкой доле пациентов, получающих ССТ.
6
Miura, K., I. Sawaki, and H. Nakajima. "Low-loss single-mode plastic waveguide fabricated by photopolymerization." In Integrated and Guided Wave Optics. Washington, D.C.: Optica Publishing Group, 1988. http://dx.doi.org/10.1364/igwo.1988.mc3.
Анотація:
Plastic materials used for optical fibers are very attractive as optical waveguides because of the simple fabrication process and their low loss. There have been several reports on plastic waveguides that were fabricated by photopolymerization of the dopant monomer[1], and some had a propagation loss as low as 0.2 dB/cm[2],[3]. However, they were 2-mode or multi-mode waveguides. We now report a single-mode waveguide using polystyrene, PSt-doped poly(methyl methacrylate), PMMA. The combination of PSt/PMMA was chosen because the refractive index of PSt (n=1.59) is considerably larger than that of PMMA (n=1.49), and the solubility of PMMA in styrene is good. The fabrication process is shown in Fig. 1. The clad solution, which consisted of 10% PMMA and 90% MMA, was spin-coated at 3000 rpm on a Si substrate and baked at 90°C for 30 minutes. The core solution was also spin-coated on the PMMA clad film and baked at 60°C for 2 hours. The core solution consisted of 12% PMMA, 72% styrene, 8% aceto-phenone photoinitiater, and 8% 1,4-dioxane. The film thickness was 2 μm for the clad and 3 μm for the core. The styrene monomer for the waveguide region was polymerized by UV-light exposure through a photomask, and the unreacted monomer was removed by postbaking at 90°C for 30 minutes. Figure 2 shows the refractive index change as a function of exposure energy at the 365 nm wavelength. A maximum index change of 0.01 was obtained under this fabrication condition for the 633 nm wavelength. The channel waveguides were fabricated using a photomask which included 1- to 10-μm-wide, 60-mm-long straight waveguide patterns. Single-mode waveguides were obtained for 1 to 3 μm pattern widths with a 0.005 refractive index change. Propagation loss was measured by detecting the scattered light along the waveguide[4] (Fig. 3). The input light from the He-Ne laser was coupled through a microscopic objective lens to the waveguide and scattered light was collected by a 0.9-mm-core plastic fiber. A propagation loss of 0.1 dB/cm was obtained for the single mode waveguide (2- to 3-μm pattern width).
7
Béland, Mathieu, Alain deChamplain, Smail Kalla, and Etienne Robert. "Scaling Methodology of the FAA Burner for Pre-Qualification Fire Tests of Aircraft Engine Panels." In ASME Turbo Expo 2019: Turbomachinery Technical Conference and Exposition. American Society of Mechanical Engineers, 2019. http://dx.doi.org/10.1115/gt2019-91937.
Анотація:
Abstract The main objective of this work is to design a small kerosene burner to study the fireproofing capacity of aircraft composite materials exposed to an open flame. The standards AC20-135 and ISO-2685 describe how the fireproofing tests have to be performed and serve as guidelines to set the requirements for the design of a small kerosene burner as a less costly alternative to the larger FAA burner. The burner is fed with liquid jet-A fuel and air, which is flowing around the injector in a cylindrical chamber. The combustion generates an unconfined flame. The fuel injector selected is a Delavan spill-return pressure atomizer. There is a custom 3D printed plastic axial swirler at the inlet of the combustion area to promote better mixing between air and jet-A droplets. A computational fluid dynamic analysis (CFD) is presented to better understand the aerodynamic of the burner and to design adequately the swirler. The design of the burner allows changing easily the swirler to test swirlers with different vane angles. An experimental test bench is designed to test the effect of these swirlers on the heat flux measurements under multiple combinations of burner power and equivalence ratio at four axial locations. The experimental investigation allows selecting the final configuration and parameters for the burner. The chosen swirler has 15 vanes that are oriented at the exit at 25° to the burner axis. The best axial location for the measurements from the burner face to the position of the calorimeter is at 7.6 cm (3 in.). It is possible to generate a flame with a diameter smaller than 6.4 cm (2.5 in.) while reaching the required heat flux of 116 kW/m2. This accommodates smaller coupon sizes for the composite material and reduces cost for pre-certification FAA testing. To achieve this flame configuration, the burner power should be set between 10 kW and 20 kW with an equivalence ratio from 0.7 to 0.9.
8
Пронин, Е. В., М. Б. Анциферов, Т. М. Алексеева, А. М. Лапшина та В. С. Пронин. "ИСПОЛЬЗОВАНИЕ ФАРМАКОТЕРАПЕВТИЧЕСКОГО ТЕСТИРОВАНИЯ ДЛЯ ПРОГНОЗА ДОЛГОСРОЧНОЙ ЭФФЕКТИВНОСТИ АНАЛОГОВ СОМАТОСТАТИНА 1-Й ГЕНЕРАЦИИ У ПАЦИЕНТОВ С СИНДРОМОМ АКРОМЕГАЛИИ". У X (XXIX) НАЦИОНАЛЬНЫЙ КОНГРЕСС ЭНДОКРИНОЛОГОВ с международным участием «Персонализированная медицина и практическое здравоохранение». ФГБУ «НМИЦ эндокринологии» Минздрава России, 2023. http://dx.doi.org/10.14341/cong23-26.05.23-178.
Анотація:
Биохимический и опухолевый ответ на лечение аналогами соматостатина 1-й генерации (АС1) зависит
от мембранной плотности 2-го подтипа (п/т) соматостатиновых рецепторов (СР) и интактности пострецепторных механизмов в опухолевых клетках. В отличие от плотногранулированных соматотрофных опухолей
(ПСО), редкогранулированные соматотрофные опухоли (РСО) отличаются низкой плотностью 2-го п/т СР,
агрессивным течением и резистентностью к АС1. Поскольку АС1 являются препаратами 1-й линии, то с учетом морфофункциональной гетерогенности соматотрофных опухолей актуальным является определение
клинических и иммунофенотипических предикторов, позволяющих на ранних этапах прогнозировать
эффективность медикаментозной терапии (МТ) АС1.
ЦЕЛЬ: оценка информативности фармакотерапевтического тестирования (% снижения уровня ИРФ-1
через 3 и 6 месяцев от начала лечения) для прогноза рецепторного фенотипа соматотрофной опухоли
и эффективности МТ АС1.
МАТЕРИАЛЫ И МЕТОДЫ: в сравнительное исследование были включены 33 и 47 больных с ПСО и РСО,
получающих вторичную МТ вследствие нерадикальности проведенной аденомэктомии. Возраст диагноза
составил 48,4±11,4 и 39,4±12,7 лет (р=0,0027), объем резидуальной опухоли – 1,6±3,5 и 2,7±4,8 см3 (р=0,2),
исходная величина ИРФ-1 индекса [ИРФ-1/верхняя возрастная норма (ИИ)] до МТ – 2,8±0,8 и 2,7±0,9 (р=0,6),
соответственно. В лечении использовались продленные формы ланреотида и октреотида. Длительность
МТ составила 21,5±21,8 месяцев. Биохимическая ремиссия констатировалась при значении ИИ ≤1.
Контрольными точками являлись показатели ИРФ-1 до МТ, через 3, 6, 12 месяцев лечения и при последнем визите.
РЕЗУЛЬТАТЫ: итоговая величина ИИ у больных с ПСО составила 0,95±0,27 и 1,4±0,64 у пациентов с РСО,
(р=0,0002). ПСО отличались от РСО большим числом баллов 2-го п/т по IRS (10,4±2,7 против 6,7±3,5), разницей (6,1±2,7 против 0,6±4,5) и соотношением между 2-м и 5-м п/т СР (3,5±2,6 против 1,5±1,7), а также
меньшим значением Ki-67 [4,4±3,0 против 8,6±8,8%, (p<0,001)]. Процент снижения уровня ИРФ-1 через
3 и 6 месяцев лечения АС1 прямо коррелировал с экспрессией 2-го п/т по IRS (r=0,44; r=0,36), а также разницей и соотношением между 2-м и 5-м п/т СР [r=0,46; r=0,46 и r=0,41; r=0,43; (p<0,05)].
Величина снижения уровня ИРФ-1 в группах больных с ПСО и РСО составила через 3 месяца 54,8±19,6
против 28,4±23,7%, через 6 месяцев – 58,4±18,0 против 31,6±24,5%, соответственно (р=0,0002). Выявлено
наличие обратной корреляции между процентом снижения уровня ИРФ-1 через 3 и 6 месяцев лечения АС1
и итоговой величиной ИИ [r=-0,59; r=-0,72; (p <0,001)]. В ходе ROC-анализа площади под кривой информативности величин снижения ИРФ-1 через 3 и 6 месяцев для прогноза эффективности АС1 составили 0,841
и 0,853. Отрезными точками являлись снижение уровня ИРФ-1 через 3 и 6 месяцев >46 и >49% от исходного
уровня. Чувствительность данных маркеров составила 63 и 75%, специфичность – 79 и 80%.
ВЫВОДЫ:
1. Величина снижения ИРФ-1 через 3 и 6 месяцев лечения АС1 отражает выраженность экспрессии 2-го п/т
СР, а также интактность пострецепторных механизмов в опухолевых клетках.
2. Фармакотерапевтическое тестирование может использоваться в качестве дополнительного предиктора
результативности долгосрочного лечения АС1.
9
Svoboda, K., W. Denk, W. H. Knox, and S. Tsuda. "Two-photon excitation scanning microscopy with a compact, mode locked, diode- pumped Cr:LiSAF Laser." In International Conference on Ultrafast Phenomena. Washington, D.C.: Optica Publishing Group, 1996. http://dx.doi.org/10.1364/up.1996.wb.2.
Анотація:
Laser scanning microscopy combined with two-photon excitation of fluorescence holds great promise in imaging biological systems. This two-photon excitation laser scanning microscopy (TPLSM) [1] yields intrinsic submicron three-dimensional resolution with much reduced background fluorescence and thus reduced photodamage. Although the advantages of TPLSM as compared to wide field fluorescence microscopy and confocal microscopy have been demonstrated in a number of applications [2], the large cost and utility requirements of mode locked Ti:sapphire laser systems and other femtosecond light sources have kept TPLSM out of reach for most biology labs. We demonstrate here that a recently developed compact solid state laser that is mode locked with a Saturable Bragg Reflector (SBR) [3] is well-suited for TPLSM. A SBR-modelocked Cr:LiSAF laser was pumped with a 0.5 W, 670 nm diffraction-limited MOPA (SDL), providing 90 fs pulses at 860 nm with CW power of 25-44 mW per beam (Fig. la). A single beam was directed into a laser scanning microscope consisting of a pair of galvomirrors, a relay lens, a dichroic mirror, a Zeiss water-immersion objective (63 x 0.9 NA), and a photomultiplier tube for the detection of fluorescence photons [2]. Rat cortical brain slices (300 μm thick) were prepared using standard techniques. For anatomical imaging, neocortical pyramidal cells that were deeply embedded in the tissue were dialyzed and voltage clamped using whole-cell electrodes containing 500 μM fluorescein dextran (MW = 3 kD). TPLSM imaging at low magnification (Fig. 1B) revealed primary and secondary dendrites and the initial segment of the axon. At high magnification single dendritic spines, the smallest neuronal compartments, became apparent (Fig. 1C, arrow). A series of images acquired at different focal planes (Δz = 1.6 μm) demonstrates the sectioning capabilities of the microscope (Fig. 1D-F). For functional imaging of physiological calcium responses, neurons were dialyzed with electrodes containing the calcium indicator Ca-green-1 (300 μM, Molecular Probes). Ca-green is a fluorophore that undergoes a large fluorescence intensity change in response to Ca2+ binding. Intracellular free calcium concentration changes evoked by single action potentials could easily be detected (Fig. 1G).
10
Parenteau, Chantal, and Roger Burnett. "Analysis of Occupants by Seating Location, Restraint Use and Injury Risk in Tow-Away Crashes." In WCX SAE World Congress Experience. 400 Commonwealth Drive, Warrendale, PA, United States: SAE International, 2024. http://dx.doi.org/10.4271/2024-01-2752.
Анотація:
<div class="section abstract"><div class="htmlview paragraph">This study was conducted to assess the occupant restraint use and injury risks by seating position. The results were used to discuss the merit of selected warning systems. The 1989-2015 NASS-CDS and 2017-2021 CISS data were analyzed for light vehicles in all, frontal and rear tow-away crashes. The differences in serious injury risk (MAIS 3+F) were determined for front and rear seating positions, including the right, middle and left second-row seats. Occupancy and restraint use were determined by model year groups.</div><div class="htmlview paragraph">Occupancy relative to the driver was 27% in the right-front (RF) and 17% in the second row in all crashes. About 39% of second-row passengers were in the left seat, 15% in the center seat and 47% in the right seat.</div><div class="htmlview paragraph">Restraint use was lower in the second row compared to front seats. It was 43% in the right-front and 32% in the second-row seats in all crashes involving serious injury. Restraint use increased with model year groups. It was 63% in the ‘61-‘89 MY vehicles and 90% in the ‘10-‘22 MYs for drivers. The corresponding rate was 59% and 91% for right-front passengers, and 48% and 91% for second-row passengers.</div><div class="htmlview paragraph">Overall, the injury risk was 2.59% ± 0.20% for drivers, 2.52% ± 0.16% for RF passengers and 1.70% ± 0.16% for second-row passengers in all crashes. The risk was significantly higher (p<0.001) for RF passengers than for second-row occupants in all crashes. Injury risks were significantly higher in RF passengers in frontal crashes (2.58% ± 0.20% v. 1.43% ± 0.24%, p<0.001) than second-row occupants, but lower in rear crashes (0.63% ± 0.15% v. 0.99% ± 0.20%, p>0.1). The injury risk was lowest in modern (‘10-‘22 MY) vehicles compared to other model years.</div><div class="htmlview paragraph">For second-row occupants, the risk was highest in the right-rear seat in all crashes and in frontal crashes, at 1.91% ± 0.23% (1.45%-2.36% 95th CI) and 1.82% ± 0.49% (0.86-2.78 95th CI) respectively. The risk was 41% higher (p< 0.06, 0.75% diff with 0.21%-1.70% 95th CI) for right-rear than left-rear occupants in frontal crashes. The injury risks were similar in rear crashes.</div><div class="htmlview paragraph">The rear seat is still the safest seating position overall, even with lower restraint use in rear seats. Current mandated warning systems to place children in the rear seat are relevant. Regulations, policies, seatbelt laws and test programs seem successful in increasing restraint use and reducing injury rates to front-and rear-seat occupants. Some have suggested adding a warning to place children behind empty front seats if possible. This would tend to move children to the right side of the vehicle as the left front seat is always occupied. However, the results from this study showed that the overall injury risk was higher in the right-rear seat than in the left. The results were however only statistically significant in frontal impacts.</div></div>